CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response

被引：0
作者：
Pia P Wegman
Sten Wingren
机构：
[1] Faculty of Health Sciences,Department of Biomedicine and Surgery, Division of Cell Biology
来源：
Breast Cancer Research | / 7卷
关键词：
Breast Cancer; Tamoxifen; Poor Metabolizers; Postmenopausal Breast Cancer; Tamoxifen Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 34 条
[1]  
Rae JM(2005)CYP2D6 genotype and tamoxifen response Breast Cancer Res 7 E6-R290
[2]  
Goetz MP(2005)Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284-258
[3]  
Hayes DF(2005)Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 249-undefined
[4]  
Ingle JN(2004)Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52 Breast Cancer Res Treat 88 S35-undefined
[5]  
Li L(undefined)undefined undefined undefined undefined-undefined
[6]  
Storniolo AM(undefined)undefined undefined undefined undefined-undefined
[7]  
Stearns V(undefined)undefined undefined undefined undefined-undefined
[8]  
Flockhart DA(undefined)undefined undefined undefined undefined-undefined
[9]  
Wegman P(undefined)undefined undefined undefined undefined-undefined
[10]  
Vainikka L(undefined)undefined undefined undefined undefined-undefined
1234